Fluindione

DB13136ApprovedWithdrawnSmall molecule

Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior. Fluindione has been investigated for...

Mechanism: Pharmacologically active on Vitamin K epoxide reductase complex subunit 1
Curator reviewed
Formula / weight: C₁₅H₉FO₂ · 240.233 g/mol (avg)

Resolves to

Compound

UNIIEQ35YMS20QCAS957-56-2ChEMBLCHEMBL24924ChEBI134975PubChem68942

Clinical / RWD

RxNorm50097ATCB01AA12

Structure

InChIKeyNASXCEITKQITLD-UHFFFAOYSA-NSMILESFC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O

Targets

Q9BQB6VKORC1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,478Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 10 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fluindione, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In